<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>333</serviceExecutionTime><Drug id="18206"><DrugName>nicotinic acid + lovastatin, Kos/Merck KGaA</DrugName><DrugNamesKey><Name id="42964880">Advicor</Name><Name id="42787766">NLStatin</Name><Name id="42964878">Nicostatin</Name></DrugNamesKey><DrugSynonyms><Name><Value>niacin + lovastatin</Value></Name><Name><Value>NLStatin</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>niacin + lovastatin, Kos/Merck KGaA</Value></Name><Name><Value>KS-01022</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>nicotinic acid + lovastatin</Value></Name><Name><Value>Nicostatin</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Advicor</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>nicotinic acid + lovastatin, Kos/Merck KGaA</Value></Name><Name><Value>75330-75-5</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>59-67-6</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="21507">Kos Pharmaceuticals Inc</CompanyOriginator><CompaniesSecondary><Company id="1072507">AbbVie Inc</Company><Company id="13601">Abbott Laboratories</Company><Company id="18101">Merck KGaA</Company><Company id="21507">Kos Pharmaceuticals Inc</Company><Company id="26864">Bristol-Myers Squibb Pharma Co</Company><Company id="29723">Sunovion Pharmaceuticals Canada Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="18206" type="Drug"><TargetEntity id="276281" type="siDrug">Niacin/lovastatin</TargetEntity></SourceEntity><SourceEntity id="1072507" type="Company"><TargetEntity id="5037613143" type="organizationId">AbbVie Inc</TargetEntity></SourceEntity><SourceEntity id="13601" type="Company"><TargetEntity id="4295903265" type="organizationId">Abbott Laboratories</TargetEntity></SourceEntity><SourceEntity id="18101" type="Company"><TargetEntity id="4295869098" type="organizationId">Merck KGaA</TargetEntity></SourceEntity><SourceEntity id="21507" type="Company"><TargetEntity id="4295906935" type="organizationId">Kos Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="26864" type="Company"><TargetEntity id="5000211551" type="organizationId">Bristol-Myers Squibb Pharma Co</TargetEntity></SourceEntity><SourceEntity id="29723" type="Company"><TargetEntity id="5000332114" type="organizationId">Sepracor Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="1598" type="ciIndication"><TargetEntity id="10062585" type="MEDDRA"/></SourceEntity><SourceEntity id="174" type="ciIndication"><TargetEntity id="10020603" type="MEDDRA"/><TargetEntity id="D006937" type="MeSH"/><TargetEntity id="-1478187279" type="omicsDisease"/><TargetEntity id="969" type="siCondition"/></SourceEntity><SourceEntity id="1865" type="ciIndication"><TargetEntity id="10022562" type="MEDDRA"/><TargetEntity id="D007383" type="MeSH"/><TargetEntity id="-754677195" type="omicsDisease"/><TargetEntity id="261" type="siCondition"/></SourceEntity><SourceEntity id="584" type="ciIndication"><TargetEntity id="10061227" type="MEDDRA"/><TargetEntity id="D052439" type="MeSH"/><TargetEntity id="-386237446" type="omicsDisease"/><TargetEntity id="2898" type="siCondition"/></SourceEntity><SourceEntity id="2491" type="Action"><TargetEntity id="699" type="Mechanism">HDL-Cholesterol Increasing Agents</TargetEntity></SourceEntity><SourceEntity id="71" type="Action"><TargetEntity id="693" type="Mechanism">Cholesterol Absorption Inhibitors</TargetEntity></SourceEntity><SourceEntity id="205" type="Action"><TargetEntity id="437" type="Mechanism">HMG-CoA Reductase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-00943" type="ciTarget"><TargetEntity id="112452388431563" type="siTarget">3-hydroxy-3-methylglutaryl-coenzyme A reductase</TargetEntity><TargetEntity id="2750" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="W">Withdrawn</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Hypercholesterolemia - US - Jan-2002</FirstLaunched></PhaseHighestDetailed><IndicationsSecondary><Indication id="1598">Peripheral arterial occlusive disease</Indication><Indication id="174">Hypercholesterolemia</Indication><Indication id="1865">Intermittent claudication</Indication><Indication id="584">Lipid metabolism disorder</Indication></IndicationsSecondary><ActionsPrimary><Action id="205">HMG CoA reductase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="71">Antihypercholesterolemic agent</Action><Action id="2492">LDL cholesterol inhibitor</Action><Action id="2491">HDL cholesterol enhancer</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="641">Controlled release formulation</Technology><Technology id="595">Tablet formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="175">Drug combination</Technology><Technology id="805">Daily dosing</Technology></Technologies><EphmraCodes><Ephmra><Code>C10A</Code><Name>CHOLESTEROL AND TRIGLYCERIDE REDUCTION PREPARATIONS</Name></Ephmra><Ephmra><Code>C10A1</Code><Name>Statins (HMG-CoA reductase inhibitors)</Name></Ephmra></EphmraCodes><LastModificationDate>2018-12-03T09:18:15.000Z</LastModificationDate><ChangeDateLast>2018-01-23T00:00:00.000Z</ChangeDateLast><AddedDate>1998-07-14T11:00:03.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Developed by &lt;ulink linkID="21507" linkType="Company"&gt;Kos&lt;/ulink&gt;, then marketed by &lt;ulink linkID="1072507" linkType="Company"&gt;Abbvie&lt;/ulink&gt; (following its spin out from  &lt;ulink linkID="13601" linkType="Company"&gt;Abbott Laboratories&lt;/ulink&gt;, which had acquired Kos) and Canadian licensee  &lt;ulink linkID="19858" linkType="Company"&gt;Sunovion&lt;/ulink&gt; (formerly Oryx, now a subsidiary of &lt;ulink linkID="1017117" linkType="Company"&gt;Dainippon Sumitomo&lt;/ulink&gt;), and now withdrawn, Advicor (formerly Nicostatin; KS-01022) is a fixed-dose combination of the extended-release niacin product  &lt;ulink linkID="43841" linkType="Drug"&gt;Niaspan&lt;/ulink&gt; and the HMG CoA reductase inhibitor &lt;ulink linkID="44300" linkType="Drug"&gt;lovastatin&lt;/ulink&gt; [&lt;ulink linkID="406189" linkType="Reference"&gt;406189&lt;/ulink&gt;]. The product was indicated for use in patients with hypercholesterolemia when therapy with both Niaspan and lovastatin is appropriate, in combination with a cholesterol-lowering diet [&lt;ulink linkID="557253" linkType="Reference"&gt;557253&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;US launch took place in January 2002 [&lt;ulink linkID="437722" linkType="Reference"&gt;437722&lt;/ulink&gt;].      By February 2004, FDA approval had been granted for two additional tablet strengths: 500 mg niacin/20 mg lovastatin and 1000 mg niacin/20 mg lovastatin [&lt;ulink linkID="547496" linkType="Reference"&gt;547496&lt;/ulink&gt;]. By May 2006, the FDA had approved a further 1000 mg niacin/40 mg lovastatin strength product [&lt;ulink linkID="666404" linkType="Reference"&gt;666404&lt;/ulink&gt;]. By August 2006, Kos received final regulatory clearance in the UK [&lt;ulink linkID="1164302" linkType="Reference"&gt;1164302&lt;/ulink&gt;].  In December 2015, AbbVie withdrew Advicor from the market, presumably as a result of AIM HIGH results showing no benefit on cardiovascular outcomes and an increased risk for stroke for &lt;ulink linkID="43841" linkType="Drug"&gt;Niaspan&lt;/ulink&gt; plus &lt;ulink linkID="44313" linkType="Drug"&gt;simvastatin&lt;/ulink&gt;  [&lt;ulink linkID="1736488" linkType="Reference"&gt;1736488&lt;/ulink&gt;]; in April 2016, the FDA withdrew the NDA for Advicor since the benefits of the drug no longer outweighed the risks [&lt;ulink linkID="1893323" linkType="Reference"&gt;1893323&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By August 2006, Kos had filed  for US approval for the first-line treatment of mixed dyslipidemia. However, FDA approval was not granted, and no further development has been reported for this indication [&lt;ulink linkID="1164302" linkType="Reference"&gt;1164302&lt;/ulink&gt;], [&lt;ulink linkID="1164679" linkType="Reference"&gt;1164679&lt;/ulink&gt;]. Kos was previously developing Advicor for the potential treatment of intermittent claudication associated with peripheral artery disease. In January 2003, a phase III trial (ICPOP) of niacin and lovastatin, alone and in combination (Advicor), in patients with intermittent claudication was initiated [&lt;ulink linkID="587088" linkType="Reference"&gt;587088&lt;/ulink&gt;]. However, in March 2010, data were published, which showed that Advicor failed to demonstrate a clinical benefit [&lt;ulink linkID="1164592" linkType="Reference"&gt;1164592&lt;/ulink&gt;]; and by November 2010, this indication was not listed on Abbott's pipeline and development was assumed to be discontinued [&lt;ulink linkID="1164276" linkType="Reference"&gt;1164276&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;Most constraining formulation patents expired in September 2013, but &lt;ulink linkID="IN2731794" linkType="Patent"&gt;US-06080428&lt;/ulink&gt; is listed in the Orange book to May 2017. A new use patent (&lt;ulink linkID="PA3182644" linkType="Patent"&gt;US-06469035&lt;/ulink&gt;) expires in May 2018. &lt;/para&gt;&lt;para&gt;At least one company  filed an ANDA with a Paragraph IV certification in 2008, but the identity of the filer is not known, according to Thomson Reuters Newport.&lt;/para&gt;&lt;para&gt;As part of a settlement signed over &lt;ulink linkID="43841" linkType="Drug"&gt;Niaspan&lt;/ulink&gt; in April 2005, &lt;ulink linkID="14354" linkType="Company"&gt;Barr&lt;/ulink&gt; (now &lt;ulink linkID="20348" linkType="Company"&gt;Teva&lt;/ulink&gt;) was permitted to launch a generic versions of Advicor at any time from September 2013 [&lt;ulink linkID="594879" linkType="Reference"&gt;594879&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In December 2015, AbbVie withdrew Advicor from the market, presumably as a result of AIM HIGH results showing no benefit on cardiovascular outcomes and an increased risk for stroke for &lt;ulink linkID="43841" linkType="Drug"&gt;Niaspan&lt;/ulink&gt; plus &lt;ulink linkID="44313" linkType="Drug"&gt;simvastatin&lt;/ulink&gt;  [&lt;ulink linkID="1736488" linkType="Reference"&gt;1736488&lt;/ulink&gt;]; in April 2016, the FDA withdrew the NDA for Advicor since the benefits of the drug no longer outweighed the risks [&lt;ulink linkID="1893323" linkType="Reference"&gt;1893323&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2000, an NDA was filed with the FDA [&lt;ulink linkID="383544" linkType="Reference"&gt;383544&lt;/ulink&gt;]. In July 2001, Kos received an approvable letter, requiring an FDA inspection of the company's manufacturing facility  [&lt;ulink linkID="416950" linkType="Reference"&gt;416950&lt;/ulink&gt;]. A satisfactory inspection of the company's manufacturing facility was completed in August 2001 [&lt;ulink linkID="419317" linkType="Reference"&gt;419317&lt;/ulink&gt;]. In December 2001, the FDA granted approval, and US launch took place in January 2002 [&lt;ulink linkID="434026" linkType="Reference"&gt;434026&lt;/ulink&gt;], [&lt;ulink linkID="437722" linkType="Reference"&gt;437722&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By August 2006, Kos had filed for US approval of Advicor for the first-line treatment of mixed dyslipidemia. However, approval was not granted [&lt;ulink linkID="1164302" linkType="Reference"&gt;1164302&lt;/ulink&gt;], [&lt;ulink linkID="1164679" linkType="Reference"&gt;1164679&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In July 2002, Kos filed for regulatory clearance in the UK, anticipating approval in mid-2003 followed by clearance in other EU markets under the Mutual Recognition Procedure [&lt;ulink linkID="457791" linkType="Reference"&gt;457791&lt;/ulink&gt;]. In February 2004, Advicor was still awaiting UK approval and European launch was expected in 2005 [&lt;ulink linkID="523312" linkType="Reference"&gt;523312&lt;/ulink&gt;]. By May 2006, the UK Commission on Human Medicines had issued an approvable  letter for Advicor [&lt;ulink linkID="666404" linkType="Reference"&gt;666404&lt;/ulink&gt;]; and by August 2006, Advicor had received final UK approval [&lt;ulink linkID="1164302" linkType="Reference"&gt;1164302&lt;/ulink&gt;].  In December 2015, AbbVie withdrew Advicor from the market, presumably as a result of AIM HIGH results showing no benefit on cardiovascular outcomes and an increased risk for stroke for &lt;ulink linkID="43841" linkType="Drug"&gt;Niaspan&lt;/ulink&gt; plus &lt;ulink linkID="44313" linkType="Drug"&gt;simvastatin&lt;/ulink&gt;  [&lt;ulink linkID="1736488" linkType="Reference"&gt;1736488&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Canada&lt;/subtitle&gt;In December 2003, partner Oryx filed for the Canadian approval of Advicor [&lt;ulink linkID="517007" linkType="Reference"&gt;517007&lt;/ulink&gt;]. Advicor was launched in Canada in January 2006 [&lt;ulink linkID="889407" linkType="Reference"&gt;889407&lt;/ulink&gt;]. In August 2012, the product was withdrawn in Canada [&lt;ulink linkID="1893328" linkType="Reference"&gt;1893328&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In June 2004, results of the ANTHEM study were presented at the 64th Annual Scientific Sessions of the American Diabetes Association in Orlando, FL, in which the superior effectiveness of Advicor (1000/40mg and 1500/40mg doses) versus fenofibrate (200 mg) on several blood lipid levels in patients with type 2 diabetes was demonstrated [&lt;ulink linkID="552884" linkType="Reference"&gt;552884&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2004, Kos presented data at the 53rd Annual Scientific Sessions of the American College of Cardiology in New Orleans, LA, showing Advicor as an effective treatment for cholesterol disorders associated with metabolic syndrome [&lt;ulink linkID="526642" linkType="Reference"&gt;526642&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2003, the results of the IMPACT study were presented at the American College of Cardiology annual scientific session. The data showed that Advicor was safe and tolerable across dose ranges up to 1000/40 mg niacin/lovastatin in patients who principally had elevated LDL cholesterol and elevated triglycerides. The phase IV open-label, multicenter study included 4,499 patients and evaluated the safety of Advicor in doses up to 1000/40 mg for 12 weeks of therapy. During the 12-week study, fewer than 0.5% of patients taking Advicor experienced clinically significant elevations in treatment-emergent mean liver enzyme levels and no drug-induced myopathy was observed [&lt;ulink linkID="484473" linkType="Reference"&gt;484473&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In January 2003, a randomized, double-blind, parallel-assignment, dose comparison, phase III study (&lt;ulink linkID="4729" linkType="Protocol"&gt;NCT00062556&lt;/ulink&gt;; MA-02-010403; ICPOP) was initiated in the US and Russia to evaluate the safety and efficacy of two different doses of Advicor in the treatment of patients (n = 919) with intermittent claudication, compared to diet control. The primary endpoint included the percentage change from baseline in peak walking time (PWT) and claudication onset time (COT) [1164589]. By March 2010, the study had been completed with 385 and 370 patients analysed for safety and efficacy, respectively. At that time, data were published, which demonstrated that Advicor failed to show a significant difference in overall treatment effect compared to diet control at week 28 for the coprimary endpoints of PWT and COT. The PWT was increased by 26.5% in diet control, compared to 37.8% and 38.6% for high and low niacin-statin, respectively [&lt;ulink linkID="1164592" linkType="Reference"&gt;1164592&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Results of the 16-week, randomized, open-label ADVOCATE trial were presented at the 51st Annual Scientific Session of the American College of Cardiology in Atlanta, GA, in March 2002. Various doses of Advicor, &lt;ulink linkID="2807" linkType="Drug"&gt;atorvastatin&lt;/ulink&gt; and &lt;ulink linkID="44313" linkType="Drug"&gt;simvastatin&lt;/ulink&gt; were administered to 315 patients. The drugs were evaluated against lipid parameters including LDL, HDL, triglycerides and lipoprotein (a). Patients titrated to the maximum recommended dose of Advicor (2000/40 mg) showed greater improvement in triglycerides, lipoprotein (a) and HDL than those taking atorvastatin 40 mg or simvastatin 40 mg [&lt;ulink linkID="444080" linkType="Reference"&gt;444080&lt;/ulink&gt;]. Data from this trial were published in March 2003 in the American Journal of Cardiology. At 12 weeks, Advicor increased the HDL level more effectively (19%) than Lipitor (4%) and Zocor (8%). In addition, LDL levels (-42%) and the triglyceride level (-36%) also dropped, compared to Lipitor (-45% and -30%, respectively) and Zocor (-35% and -15%, respectively) [&lt;ulink linkID="481845" linkType="Reference"&gt;481845&lt;/ulink&gt;], [&lt;ulink linkID="483462" linkType="Reference"&gt;483462&lt;/ulink&gt;]. These data were published in March 2003 [&lt;ulink linkID="483431" linkType="Reference"&gt;483431&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Also in March 2002, data were published that demonstrated that Advicor was efficacious, safe and well tolerated in 814 patients during a 1-year escalating-dose study. Advicor demonstrated a dose response efficacy in all lipid parameters with the highest dose (2000/40 mg) reducing LDL and triglycerides by 47% and 42%, respectively, while increasing HDL cholesterol by 41% for patients receiving 52 weeks of therapy. Advicor also decreased levels of Lp(a) and C-reactive protein in a dose-dependent manner by 25% and 24%, respectively, with the 2000 mg/40 mg dose. Advicor was generally well tolerated by patients with no serious adverse events observed [&lt;ulink linkID="444080" linkType="Reference"&gt;444080&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2000, Kos initiated a phase IV trial to provide additional information for physicians with respect to the benefits of Advicor therapy for patients with dyslipidemia or coronary heart disease [&lt;ulink linkID="383544" linkType="Reference"&gt;383544&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2000, interim results from an ongoing phase III, long-term study were presented at the 49th American College of Cardiology meeting in Orlando, FL. These results showed that Advicor was well tolerated and raised the HDL cholesterol level by almost 40%, whilst also lowering the triglyceride and LDL cholesterol levels [&lt;ulink linkID="359640" linkType="Reference"&gt;359640&lt;/ulink&gt;], [&lt;ulink linkID="359598" linkType="Reference"&gt;359598&lt;/ulink&gt;]. Similar data were presented in March 2003, at the Fourth Annual International HDL Cholesterol Conference, Cambridge, MA [&lt;ulink linkID="481539" linkType="Reference"&gt;481539&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A US IND was filed in May 1998 and clinical trials commenced in July 1998 [&lt;ulink linkID="291498" linkType="Reference"&gt;291498&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1072507">AbbVie Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2015-12-31T00:00:00.000Z</StatusDate><Source id="1736488" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29723">Sunovion Pharmaceuticals Canada Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2012-08-02T00:00:00.000Z</StatusDate><Source id="1893328" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1072507">AbbVie Inc</Company><Country id="US">US</Country><DevelopmentStatus id="W" sortOrder="5">Withdrawn</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2015-12-31T00:00:00.000Z</StatusDate><Source id="1736488" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="26864">Bristol-Myers Squibb Pharma Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2001-01-01T00:00:00.000Z</StatusDate><Source id="434026" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18101">Merck KGaA</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2006-12-31T00:00:00.000Z</StatusDate><Source id="889425" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="21507">Kos Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1598">Peripheral arterial occlusive disease</Indication><StatusDate>2010-11-13T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="21507">Kos Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="584">Lipid metabolism disorder</Indication><StatusDate>2008-02-08T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="21507">Kos Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1865">Intermittent claudication</Indication><StatusDate>2010-11-13T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2006-12-15T00:00:00.000Z</StatusDate><Source id="751915" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="13601">Abbott Laboratories</Company><Country id="GB">UK</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2006-12-15T00:00:00.000Z</StatusDate><Source id="751915" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18101">Merck KGaA</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2002-10-24T00:00:00.000Z</StatusDate><Source id="467836" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21507">Kos Pharmaceuticals Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2006-08-08T00:00:00.000Z</StatusDate><Source id="1164302" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21507">Kos Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2002-01-29T00:00:00.000Z</StatusDate><Source id="437722" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21507">Kos Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="584">Lipid metabolism disorder</Indication><StatusDate>2006-08-08T00:00:00.000Z</StatusDate><Source id="1164302" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29723">Sunovion Pharmaceuticals Canada Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2006-01-09T00:00:00.000Z</StatusDate><Source id="889407" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1072507">AbbVie Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2013-01-02T00:00:00.000Z</StatusDate><Source id="1353488" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1072507">AbbVie Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2013-01-02T00:00:00.000Z</StatusDate><Source id="1353488" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21507">Kos Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2001-12-19T00:00:00.000Z</StatusDate><Source id="434026" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21507">Kos Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2000-09-27T00:00:00.000Z</StatusDate><Source id="383544" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21507">Kos Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2000-03-15T00:00:00.000Z</StatusDate><Source id="359598" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21507">Kos Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate>1998-07-14T00:00:00.000Z</StatusDate><Source id="291498" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26864">Bristol-Myers Squibb Pharma Co</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2000-09-27T00:00:00.000Z</StatusDate><Source id="383544" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="26864">Bristol-Myers Squibb Pharma Co</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2000-05-05T00:00:00.000Z</StatusDate><Source id="365201" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29723">Sunovion Pharmaceuticals Canada Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2003-12-12T00:00:00.000Z</StatusDate><Source id="517007" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21507">Kos Pharmaceuticals Inc</Company><Country id="GB">UK</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="174">Hypercholesterolemia</Indication><StatusDate>2002-07-12T00:00:00.000Z</StatusDate><Source id="457791" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21507">Kos Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1865">Intermittent claudication</Indication><StatusDate>2006-05-09T00:00:00.000Z</StatusDate><Source id="666404" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21507">Kos Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1598">Peripheral arterial occlusive disease</Indication><StatusDate>2005-03-16T00:00:00.000Z</StatusDate><Source id="592017" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00943"><Name>HMG CoA reductase</Name><SwissprotNumbers><Swissprot>O08424</Swissprot><Swissprot>O24594</Swissprot><Swissprot>O26662</Swissprot><Swissprot>O28538</Swissprot><Swissprot>O51628</Swissprot><Swissprot>O59469</Swissprot><Swissprot>O64966</Swissprot><Swissprot>O64967</Swissprot><Swissprot>O74164</Swissprot><Swissprot>O76819</Swissprot><Swissprot>P00347</Swissprot><Swissprot>P04035</Swissprot><Swissprot>P09610</Swissprot><Swissprot>P12683</Swissprot><Swissprot>P12684</Swissprot><Swissprot>P13702</Swissprot><Swissprot>P14773</Swissprot><Swissprot>P14891</Swissprot><Swissprot>P16237</Swissprot><Swissprot>P16393</Swissprot><Swissprot>P20715</Swissprot><Swissprot>P29057</Swissprot><Swissprot>P29058</Swissprot><Swissprot>P34135</Swissprot><Swissprot>P34136</Swissprot><Swissprot>P43256</Swissprot><Swissprot>P48020</Swissprot><Swissprot>P48021</Swissprot><Swissprot>P48022</Swissprot><Swissprot>P51639</Swissprot><Swissprot>P54960</Swissprot><Swissprot>Q00583</Swissprot><Swissprot>Q01237</Swissprot><Swissprot>Q01559</Swissprot><Swissprot>Q03163</Swissprot><Swissprot>Q0DY59</Swissprot><Swissprot>Q10283</Swissprot><Swissprot>Q12577</Swissprot><Swissprot>Q12649</Swissprot><Swissprot>Q29512</Swissprot><Swissprot>Q41437</Swissprot><Swissprot>Q41438</Swissprot><Swissprot>Q58116</Swissprot><Swissprot>Q59468</Swissprot><Swissprot>Q5R6N3</Swissprot><Swissprot>Q9V1R3</Swissprot><Swissprot>Q9XEL8</Swissprot><Swissprot>Q9XHL5</Swissprot><Swissprot>Q9Y7D2</Swissprot><Swissprot>Q9YAS4</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="13601">Abbott Laboratories</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>2</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>5</CountTotal></Company><Company><Company id="15065">Bristol-Myers Squibb Co</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="18101">Merck KGaA</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20268">Sumitomo Chemical Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20348">Teva Pharmaceutical Industries Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>0</CountActive><CountInactive>2</CountInactive><CountTotal>2</CountTotal></Type><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>2</CountActive><CountInactive>1</CountInactive><CountTotal>3</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>c1cc(cnc1)C(=O)O</Smiles><Smiles>CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C</Smiles><Smiles>CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C.c1cc(cnc1)C(=O)O</Smiles></StructureSmiles><Deals><Deal id="112697" title="Oryx to commercialize Kos's Niaspan and Advicor in Canada"/><Deal id="117287" title="Barr to copromote and manufacture Kos' Niaspan and Advicor in the US"/><Deal id="117288" title="Merck to license Kos' Niaspan and Advicor            "/><Deal id="117289" title="Takeda and Kos to copromote Niaspan in the US"/><Deal id="119302" title="DuPont to codevelop and copromote Kos' Nicostatin against hypercholesterolemia in the US and Canada                                                             "/></Deals><PatentFamilies><PatentFamily id="103181" number="WO-02067852" title="A controlled release pharmaceutical composition"/><PatentFamily id="1354890" number="WO-09839001" title="Starter kit containing nicotinic acid compositions"/><PatentFamily id="1611184" number="WO-09906052" title="Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid"/><PatentFamily id="197067" number="CN-101669948" title="Controlled-release preparation containing nicotinic acid and lovastatin and production method thereof"/><PatentFamily id="352933" number="WO-09906046" title="Combinations of HMG-CoA reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia."/><PatentFamily id="649827" number="WO-2010010579" title="Multiple unit dosage form of niacin"/><PatentFamily id="911639" number="WO-09906035" title="Combinations of HMG-CoA reductase inhibitors and nicotinic acid compounds and methods for treating hyperlipidemia once a day at night."/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>2</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Allergan plc" id="1088700"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Abbott Laboratories" id="13601"/><CountAsOwner>5</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bristol-Myers Squibb Co" id="15065"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>2</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck KGaA" id="18101"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Sumitomo Chemical Co Ltd" id="20268"/><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Teva Pharmaceutical Industries Ltd" id="20348"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>